These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38551691)

  • 21. Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model.
    Geerts H; Spiros A; Roberts P
    Alzheimers Res Ther; 2018 Feb; 10(1):14. PubMed ID: 29394903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
    Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM
    JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective dosage and mode of exercise for enhancing cognitive function in Alzheimer's disease and dementia: a systematic review and Bayesian Model-Based Network Meta-analysis of RCTs.
    Yuan Y; Yang Y; Hu X; Zhang L; Xiong Z; Bai Y; Zeng J; Xu F
    BMC Geriatr; 2024 Jun; 24(1):480. PubMed ID: 38824515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early detection of amyloid load using
    Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
    Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial).
    Li D; Mielke MM; Bell WR; Reilly C; Zhang L; Lin FV; Yu F
    Trials; 2020 Jan; 21(1):19. PubMed ID: 31907024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.
    Lahiri DK; Farlow MR; Hintz N; Utsuki T; Greig NH
    Acta Neurol Scand Suppl; 2000; 176():60-7. PubMed ID: 11273593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
    Avgerinos KI; Ferrucci L; Kapogiannis D
    Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain.
    Henderson BW; Gentry EG; Rush T; Troncoso JC; Thambisetty M; Montine TJ; Herskowitz JH
    J Neurochem; 2016 Aug; 138(4):525-31. PubMed ID: 27246255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury.
    Olsson A; Csajbok L; Ost M; Höglund K; Nylén K; Rosengren L; Nellgård B; Blennow K
    J Neurol; 2004 Jul; 251(7):870-6. PubMed ID: 15258792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-analysis.
    Rostamzadeh A; Bohr L; Wagner M; Baethge C; Jessen F
    Neurology; 2022 Oct; 99(17):e1866-e1874. PubMed ID: 36028322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease.
    Wakabayashi T; Yamaguchi K; Matsui K; Sano T; Kubota T; Hashimoto T; Mano A; Yamada K; Matsuo Y; Kubota N; Kadowaki T; Iwatsubo T
    Mol Neurodegener; 2019 Apr; 14(1):15. PubMed ID: 30975165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Citrulline Malate Supplementation on Muscle Strength in Resistance-Trained Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Aguiar AF; Casonatto J
    J Diet Suppl; 2022; 19(6):772-790. PubMed ID: 34176406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia.
    Tomiyama T; Nagata T; Shimada H; Teraoka R; Fukushima A; Kanemitsu H; Takuma H; Kuwano R; Imagawa M; Ataka S; Wada Y; Yoshioka E; Nishizaki T; Watanabe Y; Mori H
    Ann Neurol; 2008 Mar; 63(3):377-87. PubMed ID: 18300294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.
    Hock C; Golombowski S; Müller-Spahn F; Naser W; Beyreuther K; Mönning U; Schenk D; Vigo-Pelfrey C; Bush AM; Moir R; Tanzi RE; Growdon JH; Nitsch RM
    Eur Neurol; 1998; 39(2):111-8. PubMed ID: 9520072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood and Cerebrospinal Fluid Autoantibody to Aβ Levels in Patients with Alzheimer's Disease: a Meta-Analysis Study.
    Li XW; Li XX; Liu QS; Cheng Y
    J Mol Neurosci; 2020 Aug; 70(8):1208-1215. PubMed ID: 32212051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia.
    Haglund M; Kalaria R; Slade JY; Englund E
    Acta Neuropathol; 2006 May; 111(5):430-5. PubMed ID: 16555084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
    Blennow K; Hampel H; Zetterberg H
    Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intra-gastrointestinal amyloid-β1-42 oligomers perturb enteric function and induce Alzheimer's disease pathology.
    Sun Y; Sommerville NR; Liu JYH; Ngan MP; Poon D; Ponomarev ED; Lu Z; Kung JSC; Rudd JA
    J Physiol; 2020 Oct; 598(19):4209-4223. PubMed ID: 32617993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau.
    Ray B; Reyes PF; Lahiri DK
    J Psychiatr Res; 2011 Apr; 45(4):539-47. PubMed ID: 20828718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.